Steroid sulfatase inhibitors: promising new therapy for breast cancer

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Hormone-dependent breast cancer treatment has long involved oestrogen manipulation.
• Aromatase inhibitors (AIs) are current first-line therapies for post-menopausal women but face challenges with treatment relapse and resistance.
• Steroid sulfatase (STS) is identified as a novel therapeutic target for breast cancer.

Purpose of the Study:

• To review the development of steroid sulfatase (STS) inhibitors.
• To summarize current preclinical and clinical findings on STS inhibitors.
• To highlight novel therapeutic strategies for hormone-dependent breast cancer.

Main Methods:

• Literature review of STS inhibitor development.
• Analysis of preclinical trial data for STS inhibitors.
• Summary of clinical trial outcomes for STS inhibitors.

Main Results:

• Steroid sulfatase (STS) has emerged as a promising new target in breast cancer therapy.
• Dual aromatase-sulfatase inhibitors (DASIs) demonstrate encouraging preclinical results.
• New therapeutic strategies are being developed to overcome resistance to existing treatments.

Conclusions:

• STS inhibitors represent a significant advancement in treating hormone-dependent breast cancer.
• Dual-targeting compounds like DASIs offer potential for improved patient outcomes.
• Further clinical investigation is warranted for STS inhibitors and DASIs.